Citizens JMP maintains Teleflex stock Market Perform rating

On Wednesday, Citizens JMP analyst David Turkaly maintained a Market Perform rating on Teleflex (NYSE:TFX) stock, following a review of the company’s fourth quarter 2024 results and its outlook for 2025. According to InvestingPro analysis, the company appears significantly undervalued at its current price of $140.30, with strong financial health metrics supporting its long-term potential. Turkaly’s evaluation comes in the wake of Teleflex’s announcement in late March 2025 regarding its plan to divide into two separate publicly-traded companies. This strategic move aims to create two more focused and agile entities, provisionally named "NewCo" and "RemainCo," with the separation anticipated to occur in mid-2026.

Turkaly noted that the decision to split the company was unexpected but appears to be a strategic one that could potentially yield strong financial results. However, he also mentioned that due to the lack of specific details about the transaction at this time, a thorough evaluation is not yet possible.

Teleflex, a global provider of medical technologies generating over $3 billion in annual revenue, revealed its decision to split during its fourth-quarter 2024 earnings call. The company’s intention is to streamline operations and enhance shareholder value by forming two independent companies, each with a distinct strategic focus. InvestingPro data shows the company maintains impressive financial stability with a healthy current ratio of 2.27 and has consistently paid dividends for 49 consecutive years.

The analyst reiterated the Market Perform rating, signaling a neutral stance on the stock. For deeper insights into Teleflex’s valuation and growth potential, InvestingPro subscribers can access 8 additional key ProTips and a comprehensive Pro Research Report, part of the platform’s coverage of 1,400+ US stocks. As the market awaits further details on the proposed split, the analyst’s position suggests a wait-and-see approach to Teleflex’s stock. The company’s future corporate structure and potential impacts on its financial health and growth prospects remain key points of interest for investors and analysts alike.

In other recent news, Teleflex Incorporated has announced the FDA clearance of its AC3 Range™ Intra-Aortic Balloon Pump, designed for cardiac support during patient transport scenarios. This development marks a significant addition to their medical technology offerings, with the device expected to be fully available in the U.S. by the second quarter of 2025. In parallel, Teleflex reported promising preliminary results from its Ringer™ PBC study, showcasing the device’s potential in managing coronary perforations during PCI procedures. The Ringer™ PBC has received the FDA’s Breakthrough Device Designation, signaling its promise in advancing treatment options.

Additionally, Teleflex is undergoing significant corporate restructuring with plans to acquire BIOTRONIK’s Vascular Intervention business for approximately €760 million and initiate a $300 million accelerated share repurchase program. These moves come as part of a broader strategy that includes a planned spin-off of certain business segments, expected to complete by mid-2026. This restructuring has prompted Moody’s to revise Teleflex’s outlook to negative, reflecting concerns over reduced scale and business diversity post-spin-off.

Meanwhile, Needham has maintained a Hold rating on Teleflex’s stock, citing growth concerns amidst these corporate changes. The firm’s analysis suggests the company’s shares may be undervalued, but they remain cautious due to the extended timeline before the separation’s completion. Teleflex’s strategic financial activities, including the share repurchase program, are funded through existing credit facilities and aim to enhance shareholder value.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.